

Publications Stemming From
The Progeria Research Foundation Cell and Tissue Bank
Zokinvy (lonafarnib) Pre-Clinical Drug Supply Program

[The farnesyl transferase inhibitor \(FTI\) lonafarnib improves nuclear morphology in ZMPSTE24-deficient fibroblasts from patients with the progeroid disorder MAD-B](#)

Odinammadu KO, Shilagardi K, Tuminelli K, Judge DP, Gordon LB, Michaelis S. *Nucleus*. 2023;14(1):2288476. doi:10.1080/19491034.2023.2288476

[Lonafarnib and everolimus reduce pathology in iPSC-derived tissue engineered blood vessel model of Hutchinson-Gilford Progeria Syndrome.](#)

Abutaleb NO, Atchison L, Choi L, Bedapudi A, Shores K, Gete Y, Cao K, Truskey GA. *Sci Rep*. 2023 Mar 28;13(1):5032. doi: 10.1038/s41598-023-32035-3. PMID: 36977745; PMCID: PMC10050176.

[Lonafarnib improves cardiovascular function and survival in a mouse model of Hutchinson-Gilford progeria syndrome.](#)

Murtada SI, Mikush N, Wang M, Ren P, Kawamura Y, Ramachandra AB, Li DS, Braddock DT, Tellides G, Gordon LB, Humphrey JD. *Elife*. 2023 Mar 17;12:e82728. doi: 10.7554/eLife.82728. PMID: 36930696; PMCID: PMC10023154.

[Systematic screening identifies therapeutic antisense oligonucleotides for Hutchinson-Gilford progeria syndrome.](#)

Puttaraju M, Jackson M, Klein S, Shilo A, Bennett CF, Gordon L, Rigo F, Misteli T. *Nat Med*. 2021 Mar;27(3):526-535. doi: 10.1038/s41591-021-01262-4. Epub 2021 Mar 11. PMID: 33707772.

[Progerinin, an optimized progerin-lamin A binding inhibitor, ameliorates premature senescence phenotypes of Hutchinson-Gilford progeria syndrome.](#)

Kang SM, Yoon MH, Ahn J, Kim JE, Kim SY, Kang SY, Joo J, Park S, Cho JH, Woo TG, Oh AY, Chung KJ, An SY, Hwang TS, Lee SY, Kim JS, Ha NC, Song GY, Park BJ. *Commun Biol*. 2021 Jan 4;4(1):5. doi: 10.1038/s42003-020-01540-w. Erratum in: *Commun Biol*. 2021 Mar 2;4(1):297. PMID: 33398110; PMCID: PMC7782499.